公众号 / 文章呼吸衰竭与机械通气重症综合管理与镇静镇痛

急诊医学更新:急性呼吸窘迫综合征

Emergency medicine updates: Acute respiratory distress Syndrome.
PubMed 文献 · Am J Emerg Med · 2025-06-27
一句话结论中重度ARDS应实施肺保护性通气(潮气量4-8 mL/kg预测体重、平台压≤30 cmH2O、驱动压<15 cmH2O),可考虑俯卧位通气每日至少12-16小时、糖皮质激素及肌松剂,难治性低氧血症可转至ECMO中心评估。

本文综述了急性呼吸窘迫综合征(ARDS)的循证更新。ARDS是以弥漫性严重肺部炎症导致低氧性呼吸衰竭为特征的危重症,最新概念模型基于修订版柏林定义,纳入危险因素、病因、时间、胸部影像和氧合状态。管理以通气和氧合为核心:低潮气量(4-8 mL/kg预测体重)联合平台压≤30 cmH2O与改善预后相关,目标驱动压<15 cmH2O;液体复苏应个体化,总体净中性至负平衡可能有益;中重度ARDS起病14天内可考虑糖皮质激素;严重ARDS伴难治性低氧血症或呼吸机同步不良可使用神经肌肉阻滞剂;中重度ARDS肺保护性通气无效或高呼吸机参数者可考虑俯卧位通气,每日至少连续12-16小时;难治性严重ARDS可在ECMO中心行静脉-静脉体外膜肺氧合。

要点

  • 低潮气量4-8 mL/kg预测体重联合平台压≤30 cmH2O与改善预后相关,参数应优化至驱动压<15 cmH2O。
  • 中重度ARDS起病14天内可考虑糖皮质激素,起病超过14天后给药可能 worsen 预后。
  • 中重度ARDS肺保护性通气未改善或高呼吸机参数者应考虑俯卧位通气,每日至少连续12-16小时。
  • 严重ARDS伴难治性低氧血症或呼吸机同步不良可使用神经肌肉阻滞剂。
  • 严重ARDS对低潮气量通气及其他辅助治疗难治者,可在ECMO中心行静脉-静脉ECMO。

适用人群与场景

  • 急诊科收治的危重症患者,可能需要在急诊科长时间停留的ARDS患者。

诊断标准与关键阈值

  • 最新概念模型基于修订版柏林定义,纳入危险因素、基础病因、时间、胸部影像和氧合状态。

处置流程与药物剂量

  • 通气:低潮气量4-8 mL/kg预测体重,平台压≤30 cmH2O,参数优化至驱动压<15 cmH2O。
  • 液体复苏应个体化,总体净中性至负平衡可能有益。
  • 中重度ARDS起病14天内可考虑糖皮质激素;起病超过14天后给药可能 worsen 预后。
  • 严重ARDS伴难治性低氧血症或呼吸机同步不良可使用神经肌肉阻滞剂。
  • 中重度ARDS肺保护性通气未改善或高呼吸机参数者应考虑俯卧位通气,每日至少连续12-16小时。
  • 严重ARDS对低潮气量通气及其他辅助治疗难治者,可在ECMO中心行静脉-静脉ECMO。

研究设计与关键结果

  • 本文为循证更新综述,评估了ARDS相关证据;低潮气量(4-8 mL/kg预测体重)联合平台压≤30 cmH2O与改善预后相关,参数应优化至驱动压<15 cmH2O。

对床旁实践的改变

  • 急诊科医生应了解ARDS管理要点,以改善可能在急诊科长时间停留的危重症患者的急诊救治。
  • 中重度ARDS起病14天内可考虑糖皮质激素,起病超过14天后给药可能 worsen 预后。
  • 中重度ARDS肺保护性通气未改善或高呼吸机参数者应考虑俯卧位通气,每日至少连续12-16小时。
  • 严重ARDS对低潮气量通气及其他辅助治疗难治者,可在ECMO中心行静脉-静脉ECMO。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」「证据类型、等级与局限」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

INTRODUCTION: Acute respiratory distress syndrome (ARDS) is a critical condition associated with severe morbidity and mortality. There are several components of management, and it is important for emergency clinicians to be aware of these as they manage critically ill patients who may face extended time in the emergency department.

OBJECTIVE: This paper evaluates evidence-based updates concerning ARDS.

DISCUSSION: ARDS is a condition associated with diffuse, severe lung inflammation resulting in hypoxemic respiratory failure. While there have been several definitions, the most recent conceptual model is based on the revised Berlin definition and incorporates risk factors, the underlying etiology, timing, chest imaging, and oxygenation. Management is primarily based on ventilation and oxygenation, with literature demonstrating that low tidal volumes (4-8 mL/kg of predicted body weight) with plateau pressure ≤30 cm H2O are associated with improved outcomes, and settings should be optimized to target driving pressure < 15 cm H2O. Resuscitation with intravenous fluids should be individualized, though overall a net neutral-to-negative fluid balance may be beneficial. Steroids should be considered in those with moderate-to-severe ARDS within 14 days of onset, but administration past 14 days after ARDS onset may worsen outcomes. Neuromuscular blocking agents may be used in those with severe ARDS and refractory hypoxemia or ventilator dyssynchrony. Prone positioning should be considered in patients with moderate-to-severe ARDS who fail to improve despite lung-protective ventilation or in those with high ventilator settings and should ideally be performed for at least 12-16 consecutive hours per day. Patients with severe ARDS refractory to low tidal volume ventilation and other adjunctive therapies may be managed with veno-venous extracorporeal membrane oxygenation (ECMO) at an ECMO center.

CONCLUSIONS: An understanding of literature updates can improve the ED care of patients with ARDS.

来源:Am J Emerg Med,查看原文。版权归原作者所有。

参考来源

  1. Long B, Lentz S, Gottlieb M, et al. Emergency medicine updates: Acute respiratory distress Syndrome. Am J Emerg Med. 2025. PMID: 40616875. doi:10.1016/j.ajem.2025.06.066

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。